News & Updates

Show Multimedia Only

Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma

04 Sep 2025 by

Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.

Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma

04 Sep 2025

Long-term topical corticosteroid use safe, effective in EoE

04 Sep 2025

Long-term treatment with topical corticosteroids in patients with eosinophilic esophagitis (EoE) is generally effective and safe, with only rare serious complications, reports a study.

Long-term topical corticosteroid use safe, effective in EoE

04 Sep 2025

GLP1-RAs help fight cancers in adults with overweight, obesity

03 Sep 2025 by

New research indicates that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may confer a protective effect against cancers in adults with overweight or obesity regardless of type 2 diabetes status.

GLP1-RAs help fight cancers in adults with overweight, obesity

03 Sep 2025

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

03 Sep 2025 by

The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

03 Sep 2025

Does telehealth prescribing raise risk of substance use disorder?

03 Sep 2025

Receiving a stimulant prescription for attention deficit hyperactivity disorder (ADHD) via telehealth shows no significant impact on the risk for substance use disorder (SUD) but appears to elevate the risk of subsequent stimulant use disorder (stimUD), suggests a study.

Does telehealth prescribing raise risk of substance use disorder?

03 Sep 2025

Antipsychotic drugs tied to glucose homeostasis disruption

03 Sep 2025

Treatment with antipsychotics may lead to a significant glucose homeostasis dysregulation, regardless of exposure time, dose, diagnosis, and weight gain propensity, according to systematic review and meta-analysis.

Antipsychotic drugs tied to glucose homeostasis disruption

03 Sep 2025

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Patients with type 2 diabetes mellitus (T2DM) who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have lower odds of peptic ulcer disease when compared with insulin users, as shown in a retrospective study.

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025 by

Combination treatment with the oral, highly selective FGFR4 inhibitor irpagratinib plus atezolizumab has shown promising efficacy in patients with untreated or immune checkpoint inhibitor (ICI)-exposed hepatocellular carcinoma (HCC) with fibroblast growth factor 19 overexpression (FGF19+), while being safe and well tolerated, according to the updated results of the phase II ABSK-011-201 study.